Abstract
Aim The COmparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis Trial (CONSTRUCT) aimed to compare the clinical and cost effectiveness of infliximab and ciclosporin in the treatment of steroid resistant acute severe ulcerative colitis, using quantitative, qualitative, and health economic data. The qualitative element explored patients’ and health professionals’ views of the two drugs.
Highlights
The efficacy of Infliximab and Ciclosporin for treating moderate to severe ulcerative colitis is proven, but their relative effectiveness has not been evaluated
Within a UK multi-centre open label pragmatic randomised controlled trial, 35 interviews were conducted with 20 patients and 23 health professionals involved in the trial
There was no significant difference between the two drugs in clinical effectiveness terms, incidence of serious side effects, colectomy rates or mortality
Summary
The efficacy of Infliximab and Ciclosporin for treating moderate to severe ulcerative colitis is proven, but their relative effectiveness has not been evaluated. Patient and health professionals’ perspectives on the use of ciclosporin and infliximab when treating acute severe ulcerative colitis: an added dimension to the construct trial From 3rd International Clinical Trials Methodology Conference Glasgow, UK.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
